Patent ID: 7534427

Claim:
A method for treating a B-cell-related malignancy disease in a human comprising administering to said human either (i) a conjugated anti-CD74 antibody or an antigen-binding fragment thereof and an unconjugated anti-CD20 antibody or an antigen-binding fragment thereof, wherein said conjugated anti-CD74 antibody or antigen-binding fragment thereof and said unconjugated anti-CD20 antibody or antigen-binding fragment thereof are administered concurrently or sequentially or (ii) a conjugated anti-CD20 antibody or an antigen-binding fragment thereof and an unconjugated anti-CD74 antibody, or an antigen-binding fragment thereof, wherein said conjugated anti-CD20 antibody or antigen-binding fragment thereof and said unconjugated anti-CD74 antibody or antigen-binding fragment thereof are administered concurrently or sequentially, wherein predosing with a non-radiolabeled antibody is not performed and wherein the unconjugated anti-CD20 or unconjugated anti-CD74 is added as a maintenance therapy to keep proliferating tumor cells from target escape.